Benevich Eric's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Feb 29, 2024
- Accession no.
- 0000914475-24-000082
- Filed
- Feb 29, 2024
- Trade date
- Feb 28, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $10.1M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Benevich EricCIK 0001643653 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2024 | Common Stock | MOption exerciseAcquired | +53,143 | $43.24 | +$2,297,903.32 | 93,759 | Direct | |
| Feb 28, 2024 | Common Stock | SSaleDisposed | −53,143 | $134.69 | −$7,157,830.67 | 40,616 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseAcquired | +21,857 | $79.02 | +$1,727,140.14 | 62,473 | Direct | |
| Feb 28, 2024 | Common Stock | SSaleDisposed | −21,857 | $134.69 | −$2,943,919.33 | 40,616 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2024 | Common Stock | MOption exerciseDisposed | −53,143 | $43.24 | −$2,297,903.32 | 0 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseDisposed | −21,857 | $79.02 | −$1,727,140.14 | 39,360 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.